Next Generation Sequencing (NGS) Market Outlook: A Comprehensive Analysis
The global Next Generation Sequencing (NGS) Market is forecasted to reach an estimated value of US$ 34.19 billion by 2030, expanding at a CAGR of 18.16% from 2024 to 2030, according to Renub Research. This advanced genomic technology has revolutionized DNA sequencing by enabling high-throughput and rapid analysis, significantly enhancing research across biology, medicine, and agriculture. It has also lowered the time and cost of genetic studies, making personalized medicine and diagnostics more accessible.
Revolutionizing Genomics with NGS Technology
NGS allows simultaneous sequencing of numerous DNA fragments, leading to groundbreaking discoveries in genomics, personalized healthcare, and diagnostics. The adoption of Illumina sequencing, which emerged in the mid-2000s, paved the way for faster and more affordable genetic research. NGS’s precision and scalability have transformed how scientists understand genetics, evolution, and disease mechanisms, positioning it as a vital tool in personalized medicine.
Rising Demand for Precision Medicine and Genomic Research
The increasing integration of NGS into clinical diagnostics is driving market expansion. With the technology’s ability to deliver comprehensive genetic data, NGS has gained traction in diagnosing a variety of diseases and aiding in personalized treatment decisions. The growing emphasis on precision medicine, alongside continuous innovations in genomic research, continues to broaden the scope of NGS applications, fueling the market’s growth. The transition from older technologies such as microarrays to NGS for genomic evaluation further solidifies its position in advancing diagnostics and personalized treatments.
Key Growth Regions: North America and Europe Leading the Charge
North America and Europe are at the forefront of NGS adoption, particularly in oncology and infectious disease applications. Researchers and healthcare professionals increasingly rely on NGS services to perform complex genetic analyses, while NGS panels for targeted sequencing offer cost-effective solutions for diagnostics.
The United States stands out as the largest contributor to the global NGS market. The country’s robust healthcare infrastructure, extensive research capabilities, and strong investments in genomics provide a conducive environment for NGS adoption. In September 2022, Predicine, Inc. announced the PredicineCARE™ cfDNA Assay, an NGS assay used for tumor mutation profiling in cfDNA from cancer patients. This breakthrough was granted FDA designation, underscoring the U.S.’s leadership in NGS advancements.
Reagents & Consumables: Dominating the Market
The reagents and consumables segment holds a substantial share of the global NGS market, owing to their recurring use in both commercial and research applications. These include sample preparation and target enrichment kits, which are essential for NGS processes. Pharmaceutical companies and research institutions are increasingly utilizing NGS, particularly for cancer research and diagnostics, further driving the demand for reagents and consumables.
Diagnostic Applications: Driving NGS Market Expansion
The application of NGS in diagnostics plays a critical role in the market’s growth. NGS enables precise disease diagnosis, prognosis, and personalized treatment planning, making it indispensable for oncology, rare diseases, infectious diseases, and prenatal screening. As healthcare systems prioritize precision medicine, the demand for NGS in diagnostics is expected to continue rising, contributing to the market’s rapid growth.
Sequencing by Synthesis (SBS): A Key Technology
Among the various NGS technologies, Sequencing by Synthesis (SBS) is one of the most widely used. Its accuracy and ability to generate large amounts of data at a lower cost make it ideal for research, diagnostics, and personalized medicine. As genomic analysis on a large scale becomes increasingly important, SBS technology is expected to remain a cornerstone of NGS market growth.
Fastest-Growing Segment: Academic and Clinical Research Centers
NGS is seeing increased adoption in academic and clinical research centers, particularly in cancer research. This technology allows researchers to identify new cancer-related genes, study tumor heterogeneity, and explore genetic alterations involved in tumor development. The ongoing expansion of NGS applications in research provides ample opportunities for growth in this segment.
Global Market Outlook
In addition to North America, countries across Europe (such as Germany, the United Kingdom, and France), Asia Pacific (including China, Japan, and India), and Latin America are witnessing significant advancements in NGS technology. The market’s continued growth is fueled by investments in healthcare, growing awareness of precision medicine, and governmental support for genomic research.
Related Reports:
Key Players in the NGS Market
Several major companies are driving innovations and shaping the global NGS market:
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences
- QIAGEN N.V.
- Roche
- Bio-Rad Laboratories, Inc.
- Takara Bio Inc.
- Hamilton Company
- Geneious
- BioMérieux SA
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
Website: www.renub.com